AstraZeneca PLC (LON:AZN) Receives Consensus Rating of “Moderate Buy” from Brokerages

AstraZeneca PLC (LON:AZN) has earned a consensus rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is £152.17.

Several research analysts have recently commented on the company. Citigroup lifted their price target on AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a report on Tuesday, July 28th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating and issued a £115 price objective on shares of AstraZeneca in a report on Wednesday, August 5th. Berenberg Bank restated a “buy” rating and set a £160 price objective on shares of AstraZeneca in a research report on Tuesday, July 28th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a £175 target price on shares of AstraZeneca in a research note on Monday, August 3rd.

AstraZeneca Stock Down 2.1%

Shares of LON:AZN opened at £114.60 on Friday. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 64.10. The business has a fifty day moving average of £130.25 and a two-hundred day moving average of £138.79. The stock has a market cap of £177.73 billion, a P/E ratio of 17.16, a PEG ratio of 0.86 and a beta of 0.21. AstraZeneca has a 52-week low of £107.84 and a 52-week high of £157.32.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.